Evidence map›Paper›PMID 26123600›Full record

ArticleMedical oncology (Northwood, London, England)2015

Pericyte antigens in angiomyolipoma and PEComa family tumors.

Jia Shen, Swati Shrestha, Yu-Hsin Yen, Michelle A Scott, Greg Asatrian, Raymond Barnhill, Claire Lugassy, Chia Soo, Kang Ting, Bruno Peault and 2 more

Abstract readClinical Study
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Malignant uterine PEComa: a narrative literature review and challenging case report.Journal of cancer research and clinical oncology · 2026
    Review
  2. Article
  3. Sarcoma Tumor Microenvironment.Advances in experimental medicine and biology · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Jia ShenDivision of Growth and Development, School of Dentistry, University of California, Los Angeles, CA, USA.
Swati Shrestha
Yu-Hsin Yen
Michelle A Scott
Greg Asatrian
Raymond Barnhill
Claire Lugassy
Chia Soo
Kang Ting
Bruno Peault
Sarah M Dry
Aaron W James
University of California, Los Angeles · USUniversity of California System · USNationwide Children's Hospital · USOrthopaedic Hospital · USUniversity of Edinburgh · GB

Funding

Medical Research Council G1000816
6 · The paper itself

Abstract

Perivascular epithelioid cell tumors (PEComas) are an uncommon family of soft tissue tumors with dual myoid-melanocytic differentiation. Although PEComa family tumors commonly demonstrate a perivascular growth pattern, pericyte antigen expression has not yet been examined among this unique tumor group. Previously, we demonstrated that a subset of perivascular soft tissue tumors exhibit a striking pericytic immunophenotype, with diffuse expression of αSMA, CD146, and PDGFRβ. Here, we describe the presence of pericyte antigens across a diverse group of PEComa family tumors (n = 19 specimens). Results showed that pericyte antigens differed extensively by histological appearance. Typical angiomyolipoma (AML) specimens showed variable expression of pericyte antigens among both perivascular and myoid-appearing cells. In contrast, AML specimens with a predominant spindled morphology showed diffuse expression of pericyte markers, including αSMA, CD146, and PDGFRβ. AML samples with predominant epithelioid morphology showed a marked reduction in or the absence of immunoreactivity for pericyte markers. Lymphangiomyoma samples showed more variable and partial pericyte marker expression. In summary, pericyte antigen expression is variable among PEComa family tumors and largely varies by tumor morphology. Pericytic marker expression in PEComa may represent a true pericytic cell of origin, or alternatively aberrant pericyte marker adoption. Markers of pericytic differentiation may be of future diagnostic utility for the evaluation of mesenchymal tumors, or identify actionable signaling pathways for future therapeutic intervention.

Indexed as

ActinsAdultAgedAged, 80 and overAngiomyolipomaAntigens, NeoplasmBiomarkers, TumorCD146 AntigenFemaleHumansImmunohistochemistryMaleMiddle AgedPericytesPerivascular Epithelioid Cell NeoplasmsReceptor, Platelet-Derived Growth Factor betaACTA2 protein, humanActinsAntigens, NeoplasmBiomarkers, TumorCD146 AntigenMCAM protein, humanReceptor, Platelet-Derived Growth Factor beta

Identifiers

PMID26123600
OpenAlexW1145048675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.